Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemours (CC) Asset Writedowns and Impairment (2016)

Chemours has reported Asset Writedowns and Impairment over the past 2 years, most recently at $46.0 million for Q3 2016.

  • Quarterly results put Asset Writedowns and Impairment at $46.0 million for Q3 2016, up 2.22% from a year ago — trailing twelve months through Sep 2016 was $152.0 million (up 237.78% YoY), and the annual figure for FY2015 was $48.0 million, changed.
  • Asset Writedowns and Impairment for Q3 2016 was $46.0 million at Chemours, down from $58.0 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for CC hit a ceiling of $58.0 million in Q2 2016 and a floor of $3.0 million in Q4 2015.